United Therapeutics (UTH) Stock Overview
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
UTH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
United Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$362.20 |
| 52 Week High | US$381.20 |
| 52 Week Low | US$237.40 |
| Beta | 0.62 |
| 1 Month Change | 38.56% |
| 3 Month Change | 49.92% |
| 1 Year Change | 13.94% |
| 3 Year Change | 70.45% |
| 5 Year Change | 313.94% |
| Change since IPO | 1,912.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| UTH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -3.0% | 0.4% |
| 1Y | 13.9% | -34.0% | 10.2% |
Return vs Industry: UTH exceeded the German Biotechs industry which returned -34% over the past year.
Return vs Market: UTH exceeded the German Market which returned 10.2% over the past year.
Price Volatility
| UTH volatility | |
|---|---|
| UTH Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: UTH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,305 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
| UTH fundamental statistics | |
|---|---|
| Market cap | €16.68b |
| Earnings (TTM) | €1.06b |
| Revenue (TTM) | €2.62b |
Is UTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UTH income statement (TTM) | |
|---|---|
| Revenue | US$3.08b |
| Cost of Revenue | US$339.10m |
| Gross Profit | US$2.74b |
| Other Expenses | US$1.50b |
| Earnings | US$1.24b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 27.46 |
| Gross Margin | 88.98% |
| Net Profit Margin | 40.36% |
| Debt/Equity Ratio | 0% |
How did UTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/29 18:26 |
| End of Day Share Price | 2025/09/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
United Therapeutics Corporation is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |